HG 004
Alternative Names: HG-004Latest Information Update: 03 Nov 2023
Price :
$50 *
At a glance
- Originator HuidaGene Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Retinoid isomerohydrolase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Leber congenital amaurosis
- Preclinical Retinal dystrophies
Most Recent Events
- 01 Nov 2023 Phase-I/II clinical trials in Leber congenital amaurosis in China (Ophthalmic) (NCT05906953)
- 31 Oct 2023 Phase-I/II clinical trials in Leber congenital amaurosis in USA (Ophthalmic) (NCT05906953)
- 07 Aug 2023 HG 004 receives rare pediatric drug designation for Retinal dysptophies (Inherited retinal disorders) in the US